Asthma Management Medical Slides
Generate publication-quality asthma management lecture slides in 30 seconds. AI-powered content structured for clinical education.
Generate Asthma Management DeckWhy teach Asthma Management?
Asthma affects over 300 million people globally and causes approximately 455,000 deaths annually. The GINA 2023 guidelines fundamentally shifted management by recommending as-needed ICS-formoterol as preferred reliever therapy across all severity steps, eliminating SABA-only treatment. Teaching asthma requires coverage of phenotyping, stepwise therapy, and the expanding role of biologic agents for severe disease.
What AI generates for Asthma Management
Enter “Asthma Management” and SlideCraft generates a complete lecture deck with slides like these.
Veja em ação
Digite qualquer tema médico e veja a IA gerar um slide de apresentação em segundos. Sem necessidade de cadastro.
3 previews gratuitos por hora · Sem necessidade de conta
Digite um tema e clique em Gerar para ver seu slide com IA
Asthma Management Presentation FAQ
How should the GINA 2023 stepwise approach be presented in slides?
Present both treatment tracks: Track 1 (preferred) uses as-needed low-dose ICS-formoterol (Steps 1-2) escalating to maintenance-and-reliever therapy (Steps 3-5). Track 2 uses as-needed SABA with maintenance ICS. Emphasize the paradigm shift from SABA-only to ICS-containing reliever — the SYGMA and Novel START trials showed ICS-formoterol PRN reduced exacerbations by 60% versus SABA alone.
What biologic selection criteria should be included for severe asthma?
Present biomarker-guided selection: blood eosinophils ≥150 (mepolizumab, benralizumab), ≥300 (dupilumab), FeNO ≥25 ppb (dupilumab, tezepelumab), total IgE 30-1500 + allergen sensitization (omalizumab). Tezepelumab (anti-TSLP) works across phenotypes regardless of biomarkers per the NAVIGATOR trial. Include the 2023 ERS/ATS guidelines on biologic switching after 4-6 month inadequate response.
How should acute exacerbation severity be taught in presentation format?
Use the GINA severity assessment: mild-moderate (talks in phrases, SpO2 ≥90%, PEF >50%), severe (talks in words, accessory muscles, SpO2 <90%, PEF ≤50%), life-threatening (drowsy/confused, silent chest, SpO2 <90%, PEF <25%). Present the treatment protocol: repeated SABA nebulization, ipratropium, early systemic corticosteroids, IV magnesium sulfate for severe cases. Include disposition criteria and step-up plan at discharge.
Preços simples, sem surpresas
Comece grátis hoje. Assine quando seu departamento precisar de mais.
Gratuito
Experimente o SlideCraft sem compromisso
- 2 apresentações por mês
- Slides com IA + notas do apresentador
- Visualizar e apresentar (sem exportar)
- Armazenamento na nuvem por 7 dias
- Slide Checker & Outline Generator
Pro
Para clínicos que dão aula toda semana
- 10 apresentações/mês + $2.50/extra
- Modo Crítico com IA (análise 5 eixos)
- Documento para apresentação (PDF)
- Exportar PDF, PPTX, SCORM e imagem
- Armazenamento permanente na nuvem
Expert
Para médicos acadêmicos que publicam e apresentam
- 25 apresentações/mês + $2.00/extra
- Verificação de fontes PubMed
- Pipeline artigo-para-apresentação
- Citações automáticas (Vancouver)
- Tudo do plano Pro